A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

NANot yet recruitingINTERVENTIONAL

Enrollment

785

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2026

Conditions

Coronary Artery Disease

Interventions

DEVICE

The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.

Trial Locations (5)

Beijing Anzhen Hospital Capital Medical University, Beijing

BeijingChao-YangHospital, Beijing

Nanfang Hospital, Guangzhou

Taida International Cardioascular Hospital, Tianjin

Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang UniversitySchool of Medicine, Hangzhou

All Listed Sponsors

collaborator

CCRF Inc., Beijing, China

INDUSTRY

lead

Shanghai Bio-heart Biological Technology Co., Ltd.

INDUSTRY

NCT04179045 - A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System | Biotech Hunter | Biotech Hunter